Lantheus Holdings (LNTH) Earnings Date & Reports

Key Takeaways

• Worldwide revenue reached $389.9 million in Q3 2026, up 1.5% from $384.0 million a year earlier.
• GAAP (Generally Accepted Accounting Principles) diluted earnings per share fell 19.5% to $0.33, while adjusted diluted EPS rose 32.3% to $1.68.
• Neuraceq sales jumped 123.0% to $45.6 million, while flagship PYLARIFY slipped 0.7% to $238.9 million.
• The company suspended full-year 2026 guidance and skipped its earnings call because of its pending ~$8.0 billion all-cash merger with Curium.
• Cash and cash equivalents climbed to $683.6 million as of September 30, 2026, from $359.1 million at the start of the year.
• For more context, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• You can also discover related trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Lantheus Holdings, a radiopharmaceutical company focused on diagnostic imaging and targeted therapies, reported results for the third quarter ended September 30, 2026. This quarterly earnings release arrives at a pivotal moment: the company has agreed to be acquired by Curium in an all-cash transaction valued at up to roughly $8.0 billion. Because the pending merger, announced in August 2026, dominates the investment narrative, management suspended its full-year guidance and did not hold a conference call. For investors, the report matters less as a standalone growth story and more as a check on whether the underlying franchise—led by PYLARIFY, DEFINITY, and Neuraceq—remains stable enough to support the deal's closing and any contingent payments tied to future product milestones.

Reported Results

Lantheus posted third-quarter 2026 worldwide revenue of $389.9 million, a 1.5% increase from $384.0 million in the prior-year period. GAAP net income declined 19.4% to $22.4 million, while GAAP fully diluted earnings per share fell to $0.33 from $0.41. On an adjusted (non-GAAP) basis, however, diluted EPS rose 32.3% to $1.68, compared with $1.27 a year earlier, and adjusted net income increased 34.3% to $115.1 million.

Revenue growth was uneven across the portfolio. Neuraceq, an Alzheimer's disease imaging agent, surged 123.0% to $45.6 million, and the cardiology ultrasound agent DEFINITY grew 4.8% to $85.7 million. PYLARIFY, the prostate cancer PET (positron emission tomography) imaging agent, declined 0.7% to $238.9 million. GAAP operating income decreased 26.2% to $32.2 million, pressured by higher research and development spending, while adjusted operating income climbed 28.1% to $153.2 million. The company generated $102.0 million in operating cash flow and $99.9 million in free cash flow during the quarter.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, making it a practical companion for earnings-season research. Explore the AI Screener to identify candidates that align with your own investment criteria.

Market Reaction and Investor Sentiment

With the merger agreement in place, LNTH's stock is now largely anchored to the deal terms rather than quarterly fundamentals. Curium US Holdings LLC has agreed to acquire all outstanding shares for $102.50 per share in cash, plus non-transferable CVRs (contingent value rights) offering up to an additional $12.00 per share tied to commercial milestones through 2030. As a result, near-term trading tends to track progress toward regulatory and antitrust approvals rather than earnings beats or misses. The U.S. Federal Trade Commission extended its review of the transaction in October 2026, a reminder that closing timing remains a key variable for investors. Notably, the company's decision to forgo guidance and a conference call removed some of the usual catalysts that move a stock around an earnings print.

Forward Outlook and Key Factors to Monitor

Looking ahead, the dominant story is whether the Curium transaction closes as planned, with completion currently anticipated in the first half of 2027. Antitrust and foreign direct investment approvals remain outstanding, and any delay or change in terms would directly affect shareholder value.

On the operational side, several regulatory milestones set the stage for longer-term growth. The company received FDA (Food and Drug Administration) approval for TAUKLARIFY, an F-18-labeled tau PET imaging agent for Alzheimer's disease assessment, and final FDA approval for BRAVNETSA, a lutetium-based treatment for certain neuroendocrine tumors. PYLARIFY TruVu also secured transitional pass-through payment status and a permanent reimbursement code effective October 1, 2026, supporting a phased commercial launch.

Investors should monitor the pace of PYLARIFY TruVu adoption, continued Neuraceq momentum, and any updates on the CVR milestones that could unlock additional per-share value. As always, the information here is educational and not a recommendation to buy or sell any security.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations